EVALUATION OF PREDICTIVE MARKERS IN THE OVARIAN CANCER MICROENVIRONMENT AND PERIPHERAL BLOOD

Sima Garberytė1, 2, Agata Mlynska2, 3, Karolina Žilionytė2, 3, Birutė Intaitė4, Vita Pašukonienė2

1 State Research Institute Centre For Innovative Medicine

2 Laboratory of Immunology, National Cancer Institute

3 Department of Biochemistry and Molecular Biology, Vilnius University

4 Department of Oncogynecology, National Cancer Institute

Ovarian cancer is one of the most common causes of cancer death in women. Ovarian cancer (OC) is the sixth most common cancer and the third most common cause of women's death from cancer in Lithuania. Due to the lack of specific symptoms and the lack of an effective screening method for most patients, the disease is detected only later (III and IV) stages, when the five-year survival rate is only 27% [1,2,3,4]. Identification of new predictive markers and their use as anti-cancer therapeutic targets for ovarian cancer may optimize OC diagnostics and therapy.

The aim was to identify predictive stemness (CD24, CD44, CD117, CD133, ESA), resistance (ABCB1, ABCG2, ABCC1) and markers of immunosuppression (immunosuppressive enzyme IDO, PB cytotoxic / suppressant lymphocyte populations) in human ovarian tumor microenvironment as well as in peripheral blood and to determine interactions among them.

The study population consisted of samples from patients with advanced epithelial ovarian cancer (FIGO stage IIIC/IV). Data about PB lymphocytes, stemness and resistance marker expression were obtained using the LSR II flow cytometer (BD Biosciences). IDO expression was detected by ELISA method. Finally, the correlation among these characteristics was evaluated.

We observed differences in stemness, resistance and immunosuppression marker expression in patients. Our results showed that of all the tested markers immunosuppressive enzyme IDO was proved to be versatile, because its expression correlated with increased expression of MDR transporters ABCC1 and ABCG2, with expanded population of immunosuppressive lymphocytes CD4+CD25+FoxP3+ and marker of stemness CD44.

There are significant relationships between different elements of immunosuppression, stemness and drug resistance in ovarian tumors. Further investigations are necessary to validate the significance of the relationships in larger study populations and to prove the prognostic and predictive value of selected multi-biomarker panel.


[1] Howlader N, Noone AM, Yu M, Cronin KA. Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer. Am J Epidemiol. 2012; 176(4):347-56.

[2] Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. Priimtas spaudai 2014.

[3] Syrios J, Banerjee S, Kaye SB. Advanced Epithelial Ovarian Cancer: From Standard Chemotherapy to Promising Molecular Pathway Targets - Where Are we Now? Anticancer Res. 2014; 34(5):2069-77.

[4] eco.iarc.fr [internetinė svetainė]. Lyon: International Agency for Research on Cancer. Sukurta 2012 [žiūrėta 2014 05 02]. Adresas: http://eco.iarc.fr/eucan/Country.aspx?ISOCountryCd=440